上市捷报丨沙利文祝贺益方生物科技（上海）股份有限公司成功登陆科创板(688382.SH)

Yifang Biotechnology (Shanghai) Co., Ltd. (Stock Code:688382.SH) on2022year07month25Rising to prominence on the Sci-tech Innovation Board. Yifang Biotech is an innovative pharmaceutical R&D company based in China with a global perspective, focusing on major disease areas such as oncology and metabolic diseases. Frost & SullivanFrost & Sullivan,Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') hereby warmly congratulates the company on its successful listing.

Yifang Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as 'Yifang Biotech') was established on2022year07month25The company was successfully listed on the stock market, with the number of shares issued being11,50010,000 shares, issue price per share18.12yuan.

Yifang Biotech is an innovative drug R&D enterprise based in China with a global perspective, focusing on major disease areas such as oncology and metabolic diseases. Yifang Biotech selects promising drug targets based on in-depth research and understanding of the mechanisms of disease action, designs drugs starting from the binding conformation of compounds and targets, and ensures excellent human safety while achieving precise treatment of diseases. Leveraging outstanding and rich drug development capabilities and experience, the company has independently developed a series of innovative targeted drugs protected by patents, covering tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, as well as metabolic diseases like hyperuricemia and gout. In the future, Yifang Biotech continues its concept of addressing unmet clinical needs, committed to developing innovative drugs with independent intellectual property rights, Chinese creation, and a global presence, and perseveringly providing patients with safer, more effective, and affordable treatment options.

Frost & Sullivan has long been focusing on the global and Chinese biopharmaceutical industries, publishing a large number of research reports that are widely cited in the prospectuses of leading science and technology innovation board listed companies in the industry, helping clients accelerate growth.

Market scale of targeted drugs for non-small cell lung cancer in China

With the continuous progress of molecular genetics research, studies on key gene mutations in non-small cell lung cancer have become increasingly in-depth. These genetic variations present on cancer genes can encode signaling proteins that regulate cell proliferation and survival, which has led to the development of various specific molecular targeted drugs.2020In [year], the market scale of targeted drugs for non-small cell lung cancer in China reached291Yuan. With the reform of medical insurance and the continuous emergence of domestic innovative drugs, the accessibility of targeted drugs for non-small cell lung cancer has been continuously improving. Targeted drugs for non-small cell lung cancer in ChinaThe market has huge market demand and development potential, and is expected to2025Annual achievement1,042Yuan billion, and arrived2030Further improvement in the year1,840100 million yuan.

Market scale of targeted drugs for non-small cell lung cancer in China2016 - 2030E

Data source: Analysis by Frost & Sullivan

chinaEGFRInhibitor market size

chinaEGFRThe inhibitor market from2016year22RMB 10 billion grew to2020year108yuan, with a compound annual growth rate of48.9%Due toEGFRMutation detection methods are continuously improving, allowing patients to be tested earlier and more accurately.EGFRMutated and acceptedEGFRInhibitor therapy.2020Year-end2025In [year], it is expected that ChinaEGFRThe market scale of inhibitor drugs will be27.7%The compound annual growth rate is at2025Year-on-year increase368Yuan billion, and moreover, it is expected2025Year-end2030During the year10.4%The compound annual growth rate is at2030Annual achievement602100 million yuan.

chinaEGFRMarket scale of small molecule targeted drugs2016 - 2030E

Data source: Analysis by Frost & Sullivan

globalSERDTargeted drug market size

currently globalSERDThe market scale of targeted drugs is mainly driven by the sales volume of fulvestrant, as shown from2016year8Billions decreased to2020year6billions, with a compound annual growth rate during the period-7.8%Considering future oralSERDTargeted drugs are gradually coming onto the market and may demonstrate better clinical efficacy and patient compliance. It is expected that in the future, globallySERDThe market scale of targeted drugs will expand.2020Year-end2025Year, globalSERDThe average annual compound growth rate of the targeted drug market size is about32.4%are expected to be2025Annual achievement24billion USD. In the next five years, the average annual compound growth rate will decline, but it will still maintain high-speed growth, expected to be at22.4%The average annual compound growth rate is at2030Annual achievement66billion dollars.

globalSERDDrug market size2016-2030E

Data source: Analysis by Frost & Sullivan

chinaSERDTargeted drug market size

chinaSERDThe market scale of targeted drugs is growing rapidly, from2016year1RMB 10 billion grew to2020year7Yuan, with a compound annual growth rate for the period of60.6%Expected future ChinaSERDThe market scale of targeted drugs will continue to expand, estimated2020reach2025Annual average compound growth rate29.8%The market scale is in2025Annual achievement24100 million yuan.2025Year-end2030In [Year], the average annual compound growth rate is forecasted to be28.9%ChinaSERDThe market scale of targeted drugs will be at2030Annual achievement86100 million yuan.

Data source: Analysis by Frost & Sullivan

Frost & Sullivan integrates the globe.61years of consulting experience,24Frost & Sullivan has been dedicated to serving the booming Chinese market for years, demonstrating a global perspective to help clients accelerate their business growth and achieve industry-leading benchmarks in terms of growth, innovation, and leadership. The large health industry is one of the core areas of focus for Frost & Sullivan. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare service, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listings include: Zhiyun Health (9955.HK), MeinGene6667.HK),Prenetics（NASDAQ: PRE), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leepu Biotech2157.HK), Clear Medical (1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhui Kaiman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Med66 (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature Medicine (UPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Pharma9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novartis HealthCare (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Biopharmaceuticals2633.HK), and Huang China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. According to the number of submission items, the Frost & Sullivan healthcare team is involved in medicalIPO listingMaintain an absolute leading position,2018till2021Year after year, it has always ranked first in market share.

since2019year7Since the first batch of companies on the Sci-tech Innovation Board were listed, Frost & Sullivan reports have also been widely cited in the prospectuses of leading Sci-tech Innovation Board-listed companies in the industry, including: Jicui Pharmaceutical (688046.SH), Haichuang Pharmaceutical688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Pharmaceutical Holdings (688197.SH), and Yuanbiotechnology (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and other institutions are considered one of the most powerful, professional, and influential industry research organizations in the sector. We aim to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.